WT-TCR Immunogene Therapy of Leukemia
演讲题目:WT-TCR Immunogene Therapy of Leukemia
Shao-An Xue, Distinguished Professor in Cancer Immunogene Therapy, Genetic Engineering Laboratory, School of Biological & Environmental Engineering, Xi’An University, Xi’An 710065, P. R. China
Dr Shao-An Xue has been in the field of viral oncology and cancer immunotherapy for 20 years, and has successfully developed a new strategy for cancer
immunotherapy based on T cell receptor (TCR) gene transfer. He has been able to demonstrate that T cells transduced with a TCR specific for the Wilm’s tumor antigen (WT1-TCR) can recognize their specific targets and selectively kill leukemia progenitor cells, without damage to normal CD34+ cells. In vivo studies have shown that these TCR-engineered patient’s T cells can eliminate leukemia progenitor cells in situations where control T cells prove ineffective. He received George Brecher New Investigator Award from the International Society for Experimental Hematology (ISEH) in 2005 (http://www.iseh.org/?page=PastNIRecipients) acknowledging this, and this work has progressed to a phase I/II clinical trial now (http://clinicaltrials.gov/show/NCT01621724)
Apart from developing the leukemia specific WT1-TCR, Dr Xue has also developed many other tumor specific TCRs, including EBV-TCR, CMV-TCR and HBV-TCR, and all of these TCRs are in the first in man clinical trials now. Due to his contribution and influence in the field of TCR immunogene therapy of cancer, he has been invited as Editorial Board Member on 8 international journals, at the same time, he has also served as an expert panel member on the Clinical Microbiology and Immunology panel of the European Society for Translational Medicine. Dr Xue received his PhD degree in Viral Oncology from Imperial College London, United Kingdom, in 1999.